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Organ-on-a-chip systems areminiaturizedmicrofluidic 3D human tissue
and organ models designed to recapitulate the important biological
and physiological parameters of their in vivo counterparts. They have
recently emerged as a viable platform for personalized medicine and
drug screening. These in vitro models, featuring biomimetic composi-
tions, architectures, and functions, are expected to replace the
conventional planar, static cell cultures and bridge the gap between
the currently used preclinical animal models and the human body.
Multiple organoid models may be further connected together through
the microfluidics in a similar manner in which they are arranged in
vivo, providing the capability to analyze multiorgan interactions.
Although a wide variety of human organ-on-a-chip models have been
created, there are limited efforts on the integration of multisensor
systems. However, in situ continual measuring is critical in precise
assessment of the microenvironment parameters and the dynamic
responses of the organs to pharmaceutical compounds over extended
periods of time. In addition, automated and noninvasive capability is
strongly desired for long-term monitoring. Here, we report a fully
integrated modular physical, biochemical, and optical sensing platform
through a fluidics-routing breadboard, which operates organ-on-a-chip
units in a continual, dynamic, and automated manner. We believe that
this platform technology has paved a potential avenue to promote the
performance of current organ-on-a-chip models in drug screening by
integrating a multitude of real-time sensors to achieve automated in
situ monitoring of biophysical and biochemical parameters.
organ-on-a-chip | microbioreactor | electrochemical biosensor |
physical sensor | drug screening
Drug discovery is a lengthy process associated with tremendouscost and high failure rate (1). On average, less than 1 in 10 drug
candidates are eventually approved by the Food and Drug Admin-
istration (2), during which successful transition ratios to next phases
are roughly 65, 32, and 60% for phase I, phase II, and phase III,
respectively (3). Among the primary causes of failure, nonclinical/
clinical safety (>50%) and efficacy (>10%) stand out in the front,
more than all other factors (e.g., strategic, commercial, operational)
combined (3, 4). These two major causes not only contribute to the
low success rates during the drug development but also lead to the
withdrawal of approved drugs from the market. Among all of
the drug attritions, it is estimated that safety liabilities related to
the cardiovascular system account for 45%, whereas 32% are due
to hepatotoxicity (5, 6). These high failure/attrition ratios of drugs
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in human patients are mainly attributed to the inefficient valida-
tion based on planar static cell cultures and preclinical animal
models for establishing drug efficacy and safety (7). Therefore,
there is an urgent need for the development of human-based 3D
organ models that precisely recapitulate the important physiology
and function of their counterparts in humans as viable platforms
for drug screening (8–10).
To this end, the recently emerged organ-on-a-chip systems that
combine advanced microfluidic technologies and tissue engineer-
ing approaches to simulate both the biology and physiology of
human organs have been developed (8, 11–30). These miniaturized
human organ models have several advantages over conventional
models, such as more accurate prediction of human responses and,
in particular, multiorgan interactions when different organ mod-
ules are assembled in a single fluid circuit (7, 31). Although a
majority of focus in the field has been placed on the construction
of biomimetic organ models (7, 15, 31–33), it is increasingly rec-
ognized that incorporating biosensing would allow for in situ
monitoring of the status of these miniaturized organs (9, 34). Such a
need originates from the fact that many drugs can trigger chronic
cellular reactions, whereas others may induce delayed cell re-
sponses. Conventional analytical methods require manual sample
collection from the microfluidic system, large working volumes, and
frequent system disturbance, and thus are not suitable for minia-
turized organ-on-a-chip platforms (9). Rather, an integrated system
that seamlessly combines not only organ models and microfluidic
units but also biosensors, which ideally runs in a continuous and
fully automated manner over extended periods of time, would be
very much desired. Several efforts have been initiated toward the
accomplishment of this ambitious goal. For example, prototype
microphysiometers have been developed for on-line measurement
of glucose and lactate (19, 35), oxygen (35), transepithelial electrical
resistance (24, 36, 37), ions (38), extracellular acidification rate
(pH), and protein biomarkers (39) in organ-on-a-chip systems (40–
46). However, these sensing units were either built upon a single
chip and limited in system-level integration and full automation
(19), or were designed for measurements over relatively short
periods of time in the range of minutes to hours. In addition,
despite that the available commercial sensors are able to monitor
a wide range of cellular parameters, such as the Multiparametric
BioChip-H (for measuring pH, O2, temperature, and electrical
signals) by Cellasys, GLU.K.OMETERPRO (for glucose) and
LACPRO (for lactate) by BST, and VisiSens (for 2D visualization
of pH, O2, or CO2 distributions) by PreSens, the integration of
these sensors with organ-on-a-chip platforms cannot be easily
achieved due to their incompatibility with microfluidic systems.
Here, we report the development of a fully integrated modular
platform that includes a microfluidic controlling breadboard for
timed routing of fluids, physical sensors for monitoring extracel-
lular microenvironment parameters (e.g., pH, O2, temperature),
electrochemical sensors for measuring soluble protein biomarkers,
and miniature microscopes for observation of organoid morphol-
ogies. All of the sensing could be performed through uninter-
rupted in situ monitoring. The integrated system was controlled by
a computer and operated in a completely automated manner for
at least 5 d. We analyzed the performance of the automated
microfluidic control as well as characterized the capacity of the
integrated physical and biochemical sensors. We further investi-
gated the possibility to adapt such an integrated platform for
monitoring drug-induced organ toxicity using dual-organ human
liver-and-heart-on-a-chip and liver-cancer-and-heart-on-a-chip
model systems, to demonstrate long-term assessment of chronic
drug responses and short-term evaluation of acute toxicity, re-
spectively. We believe that the platform technology described in
this paper will pave an avenue for interfacing existing biomimetic
organ-on-a-chip models to achieve automated in situ monitoring
of biophysical and biochemical parameters.
Results and Discussions
Modular Design of the Integrated Organ-on-a-Chip Platform. This
organ-on-a-chip platform was contained within a custom-designed
benchtop incubator capable of maintaining appropriate tempera-
ture and CO2 level (Fig. 1A). The on-chip valving was powered by
nitrogen pressure applied through a programmable Wago con-
troller and Festo valves (SI Appendix, Fig. S1), using a set of
MATLAB codes. These codes were written to also drive the
electrochemical station, which was annexed to a multiplexed
detector, for automated electrochemical measurements at pre-
determined time points. Physical sensing was achieved using a data
acquisition (DAQ) card connected to a LabVIEW program, and
was continuous during the entire course of experiments at a de-
sired data-sampling rate. A flow sensor was also incorporated into
the system to monitor the flow rate and potential channel block-
age and leakage.
Our integrated organ-on-a-chip platform was designed to be
modular, including a breadboard for microfluidic routing via built-
in pneumatic valves, microbioreactors for housing organoids, a
physical sensing suite for measurement of microenvironment pa-
rameters, one or multiple electrochemical sensing units for de-
tection of soluble biomarkers secreted by the organoids, a medium
reservoir, and bubble traps (Fig. 1B and SI Appendix, Fig. S2).
Individual modules were interconnected with Teflon tubes to al-
low for fluid flow. Each module in the circuit may also be indi-
vidually replaced on demand, such as the medium reservoir, the
bubble traps, and the electrochemical sensing chips.
Fig. 1. Integrated automated multiorgan-on-a-chip and sensing platform. (A)
Schematic of a full systemwhere themultiorgan-on-a-chip platformwas encased
in an in-house designed benchtop incubator, and of automated pneumatic valve
controller, electronics for operating physical sensors, potentiostat for measuring
electrochemical signals, and computer for central programmed integration of all
of the commands. (B) Schematic of the integrated microfluidic device consisting
of modular components including microbioreactors, breadboard, reservoir,
bubble trap, physical sensors, and electrochemical biosensors. Inset shows the
photograph of an integrated platform.
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Breadboard for Fluid Routing and Bubble Traps. To control the
routing of the medium to different modules at predetermined time
points, we designed a unique breadboard system with built-in
microchannels and pneumatic valves that allowed programma-
ble fluid manipulation (Fig. 2A). The fluid microchannels were
processed into hemicylindrical shapes to allow for complete sealing
when the thin-membrane valves were actuated (SI Appendix, Fig.
S3). A double-valve mechanism was also adopted to secure the fluid
sealing and prevent leakage due to the potentially high pressures at
the transition points between the breadboard and modules. In a
typical routing example, the microbioreactor(s), the physical sensing
unit, and the medium reservoir/bubble trap were constantly per-
fused through the breadboard connections to achieve organoid
culture and continuous monitoring of the microenvironment,
whereas the electrochemical sensing unit was only accessed when
necessary for biomarker measurements. Such a process could be
precisely automated by programmed actuation of the valves on the
breadboard (Fig. 2B), where the fluidic flow to the electrochemical
sensing module was suspended during regular perfusion through the
microbioreactors and the physical sensing unit, but restored by ac-
tivating the corresponding valve set. Additionally, the fluidic chan-
nels of the breadboard could be coated with a layer of endothelial
cells (SI Appendix, Fig. S4). The endothelial cells were able to
proliferate to become confluent within the channels in 14 d, where
the perfusion seemed to have aligned the cells better along the di-
rection of flow (SI Appendix, Fig. S4 E and F). These endothelialized
breadboards were not integrated for further experiments in the
current work, but rather indicated potential future function as its
own vascular module for interconnecting multiple organoids
without the need for additional vascular microbioreactors (47).
Due to the gas permeability of the polydimethylsiloxane (PDMS)
and the presence of junction points, air bubbles of different sizes
could be generated inside the microfluidics. Therefore, a minia-
turized trapping device to capture and remove these air bubbles
was designed to prevent potential interference with sensors and
optics, which is critical for proper functioning of the integrated
platform reported in this work. The bubble trap featured a 10-mm
single chamber containing micropillars with a series of uniform
diameters of 1,000, 500, and 250 μm (with spacing identical to
micropillar diameter), and a height of 200 μm, resulting in a total
chamber volume of ∼20 μL (SI Appendix, Fig. S5A). The aligned
micropillars in the fluidic layer were expected to prevent the bub-
bles from passing downstream, acting both as physical and hydro-
phobic barriers. We further added a vacuum chamber on top of the
fluidic chamber featuring the same arrangement of microposts but
a height of 100 μm and reduced side-channel length (SI Appendix,
Fig. S5B). Fig. 2C shows a schematic of the device, where each
vacuum chamber and the fluidic chamber were bonded via a thin
PDMS membrane (20-μm thick). The micropillars in the vac-
uum chamber were expected to prevent the collapse of the
membrane under negative pressure. The PDMS-based devices
were sandwiched between a pair of poly(methyl methacrylate)
(PMMA) clamps tightened by a set of screws/bolts to completely
seal the device (Fig. 2 D and E). The negative pressure was
realized by utilization of vacuum lines. The operational principle
of the bubble trap is illustrated in SI Appendix, Fig. S6. The
bubble trapping and removal in the device were then visually
validated using a dye (Fig. 2F, SI Appendix, Fig. S7, and Movie
S1). Flow sensor data further demonstrated successful bubble
removal from the microfluidic circuitry when the bubble trap
was integrated, as indicated by significantly reduced amounts
(>99%) of spikes caused by bubbles of different sizes traveling
through the flow sensor (Fig. 2 G and H, and SI Appendix,
Table S1 and Fig. S8). In addition to improving sensor per-
formance, the utilization of the bubble traps also contributed to
enhanced morphological observation of cells in the micro-
bioreactor by preventing bubble accumulation (SI Appendix,
Fig. S9). The inclusion of bubble traps into the platform was
Fig. 2. Microfluidic-based fluid routing and operations. (A) Schematic diagram showing design of the breadboard module consisting of a microfluidic layer
(red) and a pneumatic valve controlling layer (green) for microfluidic routing of different modules. (B) Photographs showing the constant routing (e.g., the
microbioreactor and mimic physical sensing unit) and timed routing (e.g., the mimic electrochemical sensing unit) via controlled valve operations. For the
constant routing, the two valves of the channels connecting to the mimic electrochemical sensing unit were closed (see signs in the panels), whereas that for
the constant routing was open, resulting in the red dye gradually being washed out from the microbioreactor, the mimic physical sensing unit, and the
breadboard by the infused blue dye (0–400 s); for the timed routing, the two valves of the mimic electrochemical sensing unit were released, whereas that for
the constant routing was closed, and therefore the blue dye was forced to flow into this unit to exchange the red dye (400–640 s). (C) Schematic diagrams
showing design of the bubble trap, which is composed of three layers: (i) a fluidic layer at the bottom with a thickness of 200 μm composed of arrays of
micropillars with different sizes (1,000, 500, and 250 μm); (ii) a thin PDMS membrane in the middle with a thickness of ∼20–200 μm; and (iii) a vacuum layer at
the top with a thickness of 100 μm composed of the same arrangement of micropillars. (D and E) Photographs showing the assembly of the bubble trap. (F)
Time-lapse images showing trapping and removal of a large air bubble with a volume of around 10 μL. (G and H) Plots showing flow rate data obtained from
a flow rate sensor in the (G) absence and (H) presence of an upstream bubble trap.
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also shown not to induce measurable evaporation and thus loss
of water for up to 7 d.
Integration of Noninvasive Biochemical, Physical, and Optical Sensors
for On-Line Organoid Monitoring. We developed label-free elec-
trochemical immunobiosensors for continual in situ monitoring
of soluble biomarkers secreted by the organoids (48, 49). Here,
we have further integrated these immunobiosensors with a set of
specifically designed microfluidic chips to achieve fully auto-
mated operations of the sensors for high-sensitivity and long-
term organoid monitoring in our platform. One critical feature
of our approach lies in the fact that the electrode surface could
not only be functionalized with specific antibodies for biomarker
binding and detection but also be regenerated upon saturation by
captured antigens (Fig. 3A). In a typical procedure, the surface of
the gold (Au) microelectrode is first coated with a self-assembled
monolayer (SAM) using 11-mercaptoundecanoic acid (11-MUA),
followed by immobilization of streptavidin (SPV) by covalent
bonding with 11-MUA through the carbodiimide reaction (50).
Afterward, desired biotinylated antibodies are attached to SPV via
strong interaction between SPV and biotin. This strong interaction
was able to maintain the stability of the functionalized antibodies
under flow conditions during the subsequent detection process. The
multistep functionalization process consumes ∼174 min.
The label-free detection mechanism of this electrochemical
immunobiosensor is based on the change of interfacial electron-
transfer kinetics of redox probe [Fe(CN)6]
4−/3− upon antibody–
antigen binding events (51). The antigen binding and measurement
processes take ∼58 min. The amount of biomarkers captured on
the functionalized electrode surface is proportional to the con-
centration in the solution, which would saturate after a few binding
events (SI Appendix, Fig. S10). To address this issue, we further
adapted a mechanism based on a dual-step cleaning process to
regenerate the electrode surface upon saturation with captured
antigens (32) (Fig. 3A and SI Appendix, Fig. S11). The first cleaning
step (10 mM H2SO4, potential, 0–1.8 V; scan rate, 100 mV·s
−1)
Fig. 3. Integration of microfluidic electrochemical and physical sensors. (A) Schematic diagram showing the functionalization and regeneration process of the electrode
for measurement of soluble antigens. (B) Photograph showing a fabricated microelectrode set containing an AuWE, an Au CE, and an Ag RE. (C) Schematic showing the
design of the multiplexed microfluidic chip for precisely timed injections of the chemicals for electrochemical detection. (D) Photograph of automated multiplexed re-
generation microfluidic chip. (E and F) EIS plot of the calibration impedance measurements obtained from 0 to 100 ng·mL−1 albumin and the corresponding calibration
curve for albumin. (G and H) EIS plot of the calibration impedancemeasurements obtained from 0 to 100 ng·mL−1 GST-α and the corresponding calibration curve for GST-
α. (I and J) EIS plot of the calibration impedance measurements obtained from 0 to 100 ng·mL−1 CK-MB and the corresponding calibration curve for CK-MB. Three
measurements on three individual electrodeswere used to plot each data point on each calibration curve. (K) The response of albumin biosensor to albumin (0.1 ng·mL−1).
(L) The response of albumin biosensor to GST-α (0.1 ng·mL−1). (M) The response of albumin biosensor to CK-MB (0.1 ng·mL−1).
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could efficiently remove the entire layer of antibody/antigen com-
plexes by breaking the thiol-Au bonds and peeling off Au atoms
from the surface of the electrode, whereas the second cleaning step
[50 mMK3Fe(CN)6, potential, −1.2 to 1.2 V; scan rate, 200 mV·s−1]
would restore the electrical current to the level of pristine electrode
surfaces. Regeneration of the electrode surface requires 18 min.
To realize these procedures, we further fabricated an in-house
microelectrode system for easy integration with microfluidic chips
(48, 49). The system consisted of three microelectrodes, a refer-
ence electrode (RE), a working electrode (WE), and a counter
electrode (CE). The CE and WE were made of Au, whereas the
RE was made of silver (Ag) (Fig. 3B and SI Appendix, Fig. S12 A
and B). Au was selected as the material for WE due to its rela-
tively good stability, favorable electron transfer kinetics with high
in-plane conductivity, biocompatibility, and its ability to readily
create covalent bonding for generating stable immobilization of
receptors onto its surface (48, 49). The annealing process allowed
us to create robust and smooth microelectrodes (SI Appendix, Fig.
S12C), enabling minimal damage to the electrodes under harsh
environments such as low and high pH solutions, corrosive sol-
vents, and application of high electrical potentials. Representative
cyclic voltammetry (CV) and electrochemical impedance spec-
troscopy (EIS) Nyquist plots are shown in SI Appendix, Fig. S13.
Both Au and Ag layers were fabricated in 500-nm thickness to
allow for repeated regeneration of the electrode surface for up to
four cycles (thus enabling five total measurements) without sig-
nificant changes in the electrode performance, including CV
current peaks and charge transfer resistance (Rct) ratios (SI Ap-
pendix, Fig. S14 A–C). Satisfactory regeneration of the electrode
surface should show peak current (IpA) at 0.14 V within the range
of 1.4 × 10−4 ± 2.2 × 10−6 during CV measurement (SI Appendix,
Fig. S14B), which typically leads to consistent electrochemical
signals across multiple regeneration cycles (<3% of variance; SI
Appendix, Fig. S14C). Only electrodes that met this standard were
used for electrochemical sensing. Atomic force microscopy images
further confirmed that the functionalized surface of the electrode
could be reversed back to its original state following the regen-
eration process (SI Appendix, Fig. S14 D–F).
According to the required reagents and procedure for the
functionalization and regeneration of the microelectrode, we
further designed a microfluidic chip containing a series of inlet
channels for long-term monitoring of organoid-secreted bio-
markers, where the electrode was irreversibly bound to the bottom
of the detection chamber with a sampling volume of 7 μL (SI
Appendix, Fig. S15A). This microfluidic chip allowed for auto-
mated switches of desired channels through programmed opera-
tion of built-in pneumatic valves for accessing a series of reservoirs
(Movie S2), achieving sequential injection of different agents for
automated functionalization of the electrode surface (SI Appendix,
Fig. S16) and subsequent regeneration. A miniature bubble trap
was built directly on top of the microelectrode chamber to effi-
ciently eliminate any bubbles that could potentially enter the
chamber and interfere with the electrochemical measurements (SI
Appendix, Fig. S17).
The microfluidic immunobiosensor chip could be further
multiplexed to measure several biomarkers (Movie S3). For exam-
ple, we designed a chip simultaneously hosting three microelectrode
sets and associated microfluidic channels/valves to achieve auto-
mated functionalization and regeneration for detection of liver bio-
markers albumin and glutathione S-transferase α (GST-α) as well as
cardiac biomarker creatine kinase MB (CK-MB) (Fig. 3 C and D).
The calibration curves of the three biomarkers, albumin (Fig. 3 E
and F), GST-α (Fig. 3 G and H), and CK-MB (Fig. 3 I and J), were
obtained using the microfluidic electrochemical immunobiosensors
to determine their performances. The three biosensors achieved high
sensitivities of 1.607, 1.105, and 1.483 log(ng·mL−1)−1, respectively,
leading to ultralow limit of detections for these biosensors with wide
dynamic detection ranges (SI Appendix, Table S2). Moreover, the
selectivity of the electrochemical immunobiosensors was evaluated.
A multiplexed chip was functionalized with albumin, GST-α, and
CK-MB antibodies on the three microelectrode sets, respectively,
after which albumin (0.1 ng·mL−1) was introduced to the detection
chambers. Albumin incubation induced the signal response of only
the albumin antibody-functionalized electrode set (Fig. 3K), whereas
both GST-α and CK-MB biosensors did not generate any significant
signals in response to albumin (Fig. 3 L and M). Similarly, GST-α
and CK-MB biosensors only responded to GST-α and CK-MB, re-
spectively (SI Appendix, Fig. S18).
One additional type of microfluidic chip was designed for the
integrated platform, where the single detection chamber was de-
veloped for single biomarker detection. This simple microfluidic
chip contained only the number of channels that were sufficient for
sampling, electrochemical detection [K3Fe(CN)6], and washing
[phosphate-buffered saline (PBS)] (SI Appendix, Fig. S15B and
Movie S4), which was suitable for off-line functionalization, single-
shot in-line detection, and disposability postmeasurement. It should
be emphasized that, during the antigen binding and electrochemical
signal measurement, the valves on any of these three different types
of sensing chips are closed to ensure no flow interference on the
electrode surface. In addition, all of the solutions involved in
functionalization, detection, and regeneration processes in-
cluding K3Fe(CN)6 are isolated from the main circulation and
are confined only within the sensing chip with the only con-
nection being a port sampling the medium from the breadboard
(Fig. 3C and SI Appendix, Fig. S15); there is no direct inter-
action between these solutions and the organoids, eliminating
any potential toxic effects.
Significantly, the immunobiosensing mechanism developed here
is universal. By using corresponding antibodies, these functionalized
electrochemical biosensors were capable of measuring a wide range
of soluble biomarkers secreted by the liver organoid (e.g., α-1
antitrypsin, transferrin, and ceruloplasmin), cardiac organoid (e.g.,
troponin I), and vascular organoid (e.g., von Willebrand factor) (SI
Appendix, Fig. S19). The stability and sensitivity of the sensors could
be further tuned by switching the antibodies to desired aptamers
(49), which are short-chain nucleic acids that generally known to
possess higher specificity toward antigens and stability under a wide
range of conditions than protein-based antibodies. In addition, our
impedance-based immunobiosensors measure the charge transfer
from the electrode and antigen-captured bioreceptors in the pres-
ence of K3Fe(CN)6 solution, which are potentially less affected by
the interferrants present in the medium.
A physical sensing unit integrated with optical pH and oxygen
sensors and a temperature probe was used to monitor the micro-
environment of the organoid platform (SI Appendix, Fig. S20A). The
optical pH sensor was designed to detect the absorption (>515 nm)
of the culture medium supplemented with phenol red that indicated
the pH value (SI Appendix, Fig. S20B). The optical pH sensor
module was calibrated with media at different pH values (6.5–8.0),
which generated a linear response with a sensitivity of 0.159 V·pH−1
(SI Appendix, Fig. S20 C and D). An optical oxygen sensor was
developed based on the oxygen-sensitive fluorescence of a ruthe-
nium dye (SI Appendix, Fig. S20E) (52). Characterization of the
optical oxygen sensor was performed in media containing a series of
nitrogen and air concentrations. The oxygen sensor presented a
relatively rapid response to oxygen level changes, and a linear re-
gression with a sensitivity of 7 mV·O2%
−1 (SI Appendix, Fig. S20 F
andG). Optical methods were chosen due to their suitability for on-
line monitoring of the microenvironment over extended periods of
time. The temperature sensor also showed a stable measurement
of the temperature in the benchtop incubator over a period of
7 d (SI Appendix, Fig. S20H). Minimicroscopes positioned at the
bottom of the microbioreactors fabricated by our established
method (53) were used to monitor the status of hepatic and
cardiac organoids in situ by recording their morphologies in real
time (SI Appendix, Fig. S20I). A HepG2 liver microbioreactor
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showed progressive proliferation of the hepatocytes (SI Appen-
dix, Fig. S20J), whereas the contraction of the cardiac organoids
in the microbioreactor could also be monitored (SI Appendix,
Fig. S20 K and L, and Movie S5). The beating signals were
subsequently used in analyzing drug-induced cardiotoxicity in
our organ-on-a-chip platforms.
Microbioreactors for Organoid Construction. A resealable micro-
bioreactor for perfusion culture of organoids was developed by
modifying our recently published protocols (48, 54, 55). The
microbioreactor was designed to possess two hemichambers
embedded within a pair of PDMS (top) and PDMS/glass (bot-
tom) pieces, which were then sandwiched between two rigid
supports made of PMMA and a thin PDMS cushion layer to
ensure hydraulic tightness (Fig. 4A and SI Appendix, Fig. S21).
The pair of PDMS layers together formed the microbioreactor
chamber at a thickness of ∼1.5 mm when secured together under
slight compression (Fig. 4 A and B). The thickness of the bottom
chamber was ∼250 μm, whereas that of the top chamber was
1.5 mm. The main chamber was square (7 × 7 mm2) with tapered
edges, and connected with the inlet and outlet channels on two
sides, resulting in a total working volume of ∼120 μL. Turbulent
or stagnation zones and bubble formation were minimized by
such a design due to the progressive increasing and decreasing
width of the chamber, as well as the presence of rounded cor-
ners. In addition, the microbioreactor featured a circular open-
ing in the center of the PMMA support at the bottom to enable
direct microscopic monitoring of the behavior and morphol-
ogy of the organoids without the need of disassembling the
microbioreactor (Fig. 4A).
Specifically, we demonstrated the construction of two proto-
types of human organoids in these bioreactors, liver and heart.
Although these organoid models were simplified and did not
recapitulate the full biological functions, they, however, were
sufficient to validate the capability of our in situ biosensors. The
liver organoid was constructed using a micropatterning tech-
nique through a photomask containing arrays of lobule-like
structures with a diameter of 400 μm (Fig. 4C and SI Appendix,
Fig. S22A). Human primary hepatocytes were encapsulated in
5 wt% gelatin methacryloyl (GelMA) and loaded into the bot-
tom chamber of the microbioreactor, which was subsequently
photo–cross-linked against the mask to generate a 3D human
primary liver organoid. The patterning was clearly transferred
from the photomask (Fig. 4 D and E), leading to the formation of
hepatic lobules resembling those in vivo. Live/dead staining
performed immediately after the photopatterning showed a high
viability (>90%) of the primary hepatocytes (Fig. 4F), indicating
that the photo–cross-linking procedure was not harmful to the
cells. The hepatocytes could maintain a viability of >85% over a
culture period of up to 5 d (Fig. 4G). This culture time induced
an aggregation of the primary hepatocytes without an increase in
cell number. The liver organoids remained functional, indicating
sustained secretion of albumin measured by electrochemical
biosensors (SI Appendix, Fig. S23).
The cardiac organoid was also fabricated using the micro-
patterning technique where a photomask possessing parallel
lines of 50 μm in width with 50-μm spacing was used to pattern
the 5 wt% GelMA at the bottom of the microbioreactor chamber
(56) (Fig. 4H and SI Appendix, Fig. S22B). To enhance the ad-
hesion of the cells, the patterned GelMA surface was further
coated with a layer of fibronectin. Then human induced plurip-
otent stem cell-derived cardiomyocytes (iPSC-CMs) were seeded
onto the patterns. Another layer of fibrin gel with a thickness of
∼200 μm was gently placed on top of the seeded cardiomyocytes
Fig. 4. Construction of the microbioreactor and hepatic/cardiac organoids. (A) Schematic diagrams showing the fabrication of resealable microfluidic
microbioreactor. (B) Photographs showing top view and side view of the microbioreactor. (C) Schematics indicating the construction of the hepatic organoid
via direct photopatterning of hepatocytes encapsulated inside GelMA. (D and E) Optical micrographs showing the lobule-like patterns generated for the
hepatic organoid in the microbioreactor. (F and G) Live/dead analysis showing the viability of the patterned human primary hepatocytes at day 1 and day 5 of
culture, respectively. (H) Schematics indicating the construction of the cardiac organoid, where iPSC-CMs were first seeded on top of aligned GelMA patterns
followed by coverage by a layer of fibrin to protect the cells from shear stress. (I and J) Optical micrographs showing the generated cardiac organoid featuring
highly aligned human iPSC-CMs. (K) Sarcomeric α-actinin (red), connexin-43 (green), and nuclei (blue) staining of the iPSC-CMs at day 3 of culture indicating
the alignment of the cells and well-developed contractile phenotype and intercellular junctions. The Inset is live/dead analysis showing high viability of the
iPSC-CMs. (L) Beating analysis of the cardiac organoid inside the microbioreactor.
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to enhance the spreading of iPSC-CMs and prevent direct exposure
to fluid flow. The iPSC-CMs started to align themselves with
the GelMA pattern as early as day 1 postseeding; alignment and
stretching of the cells were observed at days 3–4 (Fig. 4 I and J).
The iPSC-CMs maintained high viability (Fig. 4K, Inset), which also
showed strong expression of the contractile marker sarcomeric
α-actinin and junction protein connexin-43 (Fig. 4K), indicating
maturation of the cardiomyocytes on the patterns. The chosen
feature size of the patterns allowed the aligned cardiomyocytes to
form cellular bridges between the ridges (56), leading to strong
and synchronized beating of the cardiac organoids at a rate of ∼60
beats·min−1 (Fig. 4L and Movie S6), where the beating rates
within a single batch of cells were uniform. The cardiac organoids
remained functional showing consistent beating for up to 5 d in
culture in the bioreactors (SI Appendix, Fig. S24).
Fully Integrated Human Liver (Cancer)- and Heart-on-Chips for Automated
Drug Screening. Automation is strongly preferred to minimize
human labor especially when samples require high-throughput
or long-term analysis. After validating the functions of indi-
vidual components including the breadboard, bubble trap,
electrochemical immunobiosensor, physical sensors, minimicroscope,
and microbioreactors/organoids, we subsequently assembled these
modular units into a fully integrated system that supported com-
plete automation (Fig. 1). Specifically, two dual-organ platforms
were assembled, human heart-and-liver-on-chips, and human heart-
and-liver-cancer-on-chips, to demonstrate long-term monitoring of
chronic drug responses and short-term evaluation of acute toxicity,
respectively. The functionality of the dual-organ platform was first
validated using capecitabine, a prodrug that can undergo enzymatic
activation by hepatocytes to the active form 5-fluorouracil (5-FU),
which is a thymidylate synthase inhibitor thus inhibiting DNA syn-
thesis (57). Once converted to 5-FU, it would exert increased car-
diotoxicity compared to capecitabine (58). Indeed, we were able to
reproduce such a process using our human heart-and-liver-on-chips
platform (SI Appendix, Fig. S25A) and human heart-on-chip plat-
form (SI Appendix, Fig. S25B), where pronounced enhancement of
cardiotoxicity could only be observed when the liver organoid was
present in the dual-organ system (SI Appendix, Fig. S25C).
In the healthy group (Fig. 5A), human cardiac organoids de-
rived from iPSC-CMs and human liver organoids derived from
primary hepatocytes were linked together for up to 120 h, where
acetaminophen (APAP) was used as a model pharmaceutical
compound. APAP is a nonsteroidal antiinflammatory drug and the
primary cause of induced acute liver failure in the United States
(2), where it causes hepatotoxicity via necroapoptotic mechanisms
(59). Doses of 0, 5, and 10 mM, as determined in our previous
work (54), were introduced into the dual-organoid system at 72 h,
to demonstrate the capability of our integrated sensors for
detecting dose-dependent APAP toxicity toward the organoids.
All three physical parameters (pH, O2, and temperature) were
constantly monitored, which showed stable values over the entire
period without much disturbance from drug administrated (Fig. 5
B–D). The relatively stable O2 levels observed could be attributed
to the gas permeability of the PDMS devices; because the flow
rate used for perfusion was relatively low (200 μL·h−1), by the time
that the medium passing by the liver organoid reached the oxygen
sensor it would have been recalibrated to the ambient oxygen
level. In addition, a conventional end-point cell viability assess-
ment at 120 h presented dose-dependent toxic effect of APAP on
the survival of the hepatocytes (Fig. 5 E and F, and SI Appendix,
Fig. S26). More interestingly, the noninvasive biomarker analysis
achieved by electrochemical immunobiosensors revealed that the
secreted levels of albumin and GST-α decreased and increased,
respectively, in a dose-dependent manner (Fig. 5 G and H). This
is consistent with the hepatotoxicity induced by APAP measured
by the viability assay. CK-MB secretion by the cardiac organoid,
however, showed only minor elevation (Fig. 5I), corresponding
to their slightly reduced beating rates upon APAP treatment
(Fig. 5J), as reported previously (60).
In the liver cancer group (Fig. 6A), human cardiac organoids
derived from iPSC-CMs and human hepatic organoids derived
from HepG2/C3A hepatocellular carcinoma cells were linked
together for up to 24 h to investigate the acute toxicity upon drug
treatment. Doxorubicin (DOX), a well-known chemotherapeutic
drug, was used to ablate the liver cancer organoid (61). Using
toxic doses of 5 and 10 μM, we expected a detrimental effect on
HepG2 cells while also inducing severe cardiotoxic side effects
Fig. 5. Automated in-line sensing of APAP-induced organoid toxicity from normal human heart-liver-on-chips. (A) Schematic diagram of biomimetic human
heart-liver-on-chips. (B–D) Continual measurements of temperature, pH, and O2 concentration within the integrated heart-liver-on-chips. (E–I) Integrated
primary hepatic and iPSC-cardiac dual-organoid platform: (E) live/dead staining of the hepatic organoids post treatment with 0, 5, and 10 mM APAP, at the
end of 120 h. The drugs were introduced into the system at 72 h. (F) Normalized cell viability in the presence of APAP from day 1 to day 5. (G–I) In-line
automated electrochemical measurements of albumin and GST-α secreted from the hepatic organoids as well as CK-MB from the cardiac organoids.
(J) Beating analysis of the cardiac organoids. Red arrows indicate the time of drug addition (72 h).
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(62). Indeed, the liver cancer organoid underwent significant
death upon drug treatment (Fig. 6 B and C, and SI Appendix, Fig.
S27), accompanied by diminished secretion of albumin with a
significant release of cytoplasmic GST-α (Fig. 6 D and E).
Contrary to APAP treatment, administration of DOX induced
pronounced cardiotoxicity, as demonstrated by rounding, de-
tachment, and death of the iPSC-CMs (Fig. 6F). Caspase-3
staining further indicated apoptosis of the iPSC-CMs with ele-
vated dose of DOX (SI Appendix, Fig. S28). The level of CK-MB,
as measured by the electrochemical biosensor, surged to ex-
tremely high values (Fig. 6G), which was associated with ar-
rhythmic beating of the cardiac organoid recorded by the
minimicroscope (Fig. 6H).
It should be noted that, due to the noninvasiveness of our
electrochemical biomarker analyses, we were able to continually
monitor individual dual-organ platforms in an automated mode by
dynamically sampling the media at predefined time points (Figs. 5
G–J and 6 D, E, G, and H). As such, the measurements would be
continuous and accurate for an individual organoid pair as
opposed to the conventional end-point assays where average
values from multiple organoids need to be obtained. However,
results derived from parallel systems might still be averaged to
understand the collective statistical effects of the pharmaceu-
tical compounds applied to the organoids (SI Appendix, Figs.
S29 and S30).
To further prove the ability of physical sensors to monitor cel-
lular responses upon microenvironmental stimulation, they were
integrated with an additional platform containing a liver cancer
bioreactor (SI Appendix, Fig. S31A). Hyperthermia treatments of
the liver cancer organoids were subsequently conducted, where
the temperatures in parallel groups were rapidly increased to 41,
43, and 45 °C, respectively, held for 30 min, and allowed to reverse
to the baseline at 37 °C (SI Appendix, Fig. S31B) (63). The changes
in the pH and oxygen levels in the medium due to the metabolism
of the hepatocellular carcinoma cells were continuously measured
(SI Appendix, Fig. S31 C and D). We observed reduced metabolic
rate as the hyperthermic temperature was elevated to 45 °C pos-
sibly due to the initiation of apoptosis/necrosis of the cells (64),
where temperature increases of up to 43 °C did not seem to
have significant effect on the metabolism of the cells. The
bioreactors were completely sealed to prevent gas exchange
through the PDMS.
Conclusions and Perspectives
We have developed an automated modular design platform that
used a microfluidics-controlling breadboard for timed routing of
fluids to interface physical sensors for monitoring microenviron-
mental parameters (e.g., pH, O2, temperature), electrochemical
immunobiosensors for measuring soluble biomarkers, and minia-
ture microscopes for observation of the organoid morphologies.
All of the sensing was performed in situ in an uninterrupted and
automated manner, allowing for long-term monitoring of drug-
induced organ toxicity in a dual-organ human liver-and-heart-on-
a-chip platform insulted with APAP for up to 5 d and a dual-organ
human liver-cancer-and-heart-on-a-chip platform challenged with
DOX for up to 24 h. We believe that our integrated modular in-
line fluid routing and sensing platform will be compatible with
existing organ-on-a-chip models and will promote their perfor-
mances in drug screening by providing the capability of real-time,
in situ monitoring of their microenvironment biophysical and
biochemical parameters.
Meanwhile, we acknowledge several limitations of our current
integrated multisensor-and-organ-on-chips platform. First, the
material for making the microfluidic chips was PDMS at this
prototyping stage, which is not optimal for organs-on-chip appli-
cations due to their potential adsorption and absorption of hy-
drophobic small molecules and drugs (65, 66). For example, it was
found that DOX at higher concentrations could be partially
adsorbed/absorbed by PDMS during the 24-h period of drug
testing on the human heart-and-liver-cancer-on-chips platform (SI
Appendix, Fig. S32). To solve this issue, we have recently de-
veloped a method to fabricate thermoplastic microfluidic chips
with built-in channels as well as pneumatic valves for large-scale
fluid manipulation, which will be reported separately. Addition-
ally, it is realized that the current platform features relatively large
sizes requiring nonstandard manual assemblies as well as overly
high complexity. We believe, however, at the initial prototyping
stage such a platform has allowed us to validate our approach of
multisensor integration. Efforts have been initiated toward fur-
ther compacting and simplifying the platform by adopting LEGO
Fig. 6. Automated in-line sensing of DOX-induced organoid toxicity from heart-liver-cancer-on-chips. (A) Schematic diagram of biomimetic human heart-
liver-cancer-on-chips. (B) Live/dead staining of the liver cancer organoids post treatment with 0, 5, and 25 μM DOX, at the end of 24 h. The drugs were
introduced into the system from time 0. (C) Normalized cell viability in the presence of DOX from 6 to 24 h. (D and E) In-line automated electrochemical
measurements of albumin and GST-α secreted from the liver cancer organoids. (F) Live/dead staining of the cardiac organoids at the end of 24 h. (G) In-line
automated electrochemical measurements of CK-MB from the cardiac organoids. (H) Beating analysis of the cardiac organoids.
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and/or cartridge assemblies as recently reported for the fabrica-
tion of organs-on-a-chip models (67–71). Further efforts on im-
proved scaling of our platform should, in principle, allow for more
accurate modeling of the human system and therefore achieve
better prediction of drug efficacy/toxicity (33).
Methods
Fabrication of Breadboard. The breadboard was built using PDMS using a
standard photolithography technique. Subsequently, the microfluidic layer
master mold was converted to a convex hemicylindrical secondary mold for
generating the microchannels (SI Appendix, Fig. S3) (72). The detailed pro-
cedures are described in SI Appendix.
Fabrication of Microbioreactor. The microbioreactor was fabricated with
PDMS (SI Appendix, Fig. S21), consisting of a microfluidic perfusion layer at
the top, and a chamber layer at the bottom bonded to a piece of glass. The
detailed procedures are described in SI Appendix.
Fabrication of Bubble Trap. The bubble trap featured a 10-mm single chamber
containing micropillars with a series of uniform diameters of 1,000, 500, and
250 μm (with spacing identical to micropillar diameter), and a height of
200 μm, leading to a total chamber volume of ∼20 μL (SI Appendix, Fig. S5A). A
vacuum chamber was further added on top of the fluidic chamber featuring
the same array of micropillars but a height of 100 μm and reduced length of
side channels (SI Appendix, Fig. S5B). The detailed procedures are described in
SI Appendix.
Fabrication of Microelectrode Set. The microelectrode set was composed of
three electrodes: Au WE, Au CE, and Ag RE. The diameter of the WE was
800 μm, the width of CE and RE were 150 μm, and gap between WE and other
two electrodes was 200 μm, and the diameter of detection area was about
1,500 μm (SI Appendix, Fig. S12). The detailed procedures are described in
SI Appendix.
Integration of the Microelectrode Set with Microfluidic Electrochemical Sensing
Chip. Themicroelectrode set was bonded to the chip using air plasmawith the
detection area aligning with the chamber. The three leads of the micro-
electrode set were coated with silver epoxy (MG Chemicals) to make electrical
contact with copper wires for measurement. The detailed procedures are
described in SI Appendix.
Regeneration of Microelectrode Set-Integrated PDMS Microfluidic Chip. To
achieve long-term monitoring, the saturated microelectrode surface was
regenerated via a two-step electrochemical cleaning process: 10 mM H2SO4
followed by 50 mM K3Fe(CN)6. The H2SO4 cleaning was performed between
the electrical sweep potentials of 0.0 and 1.8 V, where the scan rate, sensitivity,
and sampling interval were set to 100 mV·s−1, 10−2 A/V, and 0.001 V, re-
spectively. The K3Fe(CN)6 cleaning was carried out between potentials of 1.0
and 0.0 V at scan rate of 200 mV·s−1, sensitivity of 10−4 A/V, and sampling
interval of 0.001 V. During the cleaning procedure, the solutions were kept
flowing at a rate of 1,000 μL·h−1. The oxidation peak current of K3Fe(CN)6
as well as Rct of the bare microelectrode were compared before and af-
ter regeneration to assess the stability and sensitivity of the regenerated
microelectrode.
Physical Sensors. The physical module housed the integrated pH and oxygen
sensors (SI Appendix, Fig. S20A). The pH sensor detected changes in the light
absorption of phenol red (Sigma-Aldrich) in the medium to translate into a
voltage change (SI Appendix, Fig. S20B). The oxygen-quenchable luminescent
dye [Ru(dpp)3]
2+Cl2–tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) chlo-
ride (Sigma-Aldrich), with an excitation wavelength at 463 nm and a maximum
emission at 618 nm, was used for the oxygen sensor (53). The detailed pro-
cedures are described in SI Appendix.
Construction of the Automation Controller. The automation controller was
constructed using a set of WAGO controllers and FESTO solenoid valves
connected to a nitrogen gas source, where each of the valves could be in-
dividually actuated using custom-coded MATLAB (Mathworks) programs to
control injection or microvalve function on the microfluidic chips (SI Ap-
pendix, Fig. S1) (73). The detailed procedures are described in SI Appendix.
Cell Culture and Patterning. Human primary hepatocytes (Triangle Research
Labs) were used to fabricate the liver organoids, and human iPSC-CMs (Stem
Cell Theranostics) were used to generate the cardiac organoids. The detailed
procedures are described in SI Appendix.
Minimicroscope. To monitor the behaviors of the organoids inside the
microbioreactors in situ, a webcam (Logitech C160)-based minimicroscope
was fabricated and fixed at the bottom of the microbioreactors (SI Appendix,
Fig. S20I). The detailed procedures are described in SI Appendix.
Drug Treatment. Two drugs were selected to test the biomimetic human dual-
organ-on-chip systems according to their target toxicity and differences among
their adverse effects in the human body, which are detailed in the main text
(Figs. 5 and 6). APAP (Sigma-Aldrich), a liver toxic drug, was administrated to
the heart-and-liver-on-chip system at dosages of 0, 5, and 10 mM based on
results obtained from our previous work (54). DOX (Sigma-Aldrich), a common
chemotherapeutic drug, was used to evaluate toxicity in the heart-and-liver-
cancer-on-chip system (62, 74). In addition, capecitabine (Sigma-Aldrich) at
80 μM was used to demonstrate the functionality of the human liver-and-
heart-on-chips platform, whereas hyperthermia treatment via elevation of
temperature of the incubation system to 41, 43, or 45 °C allowed for validation
of the utility of the physical sensors to monitor environmental stimuli-induced
changes in cell behaviors and consequent alteration in physical parameters.
The detailed procedures are described in SI Appendix.
Statistical Analysis. Sigmaplot 12.0 and Graphpad 6.0 were used to perform
statistical analysis of the experimental results. At least three samples were
analyzed per group, and a power analysis was used to determine the sample
size before each experiment.
Code Availability. MATLAB codes for measuring cardiac beating are included
in SI Appendix and Datasets S1 and S2.
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